Revised International Prognostic Scoring System for Myelodysplastic Syndrome

Loading...

References

  1. Carmelo Gurnari. Clinical-genomic profiling of MDS to inform allo-HCT: recommendations from an international panel on behalf of the EBMT.. Blood, 2025
  2. Peter L Greenberg. NCCN Guidelines® Insights: Myelodysplastic Syndromes, Version 2.2025.. Journal of the National Comprehensive Cancer Network : JNCCN, 2025
  3. E. Sauta. Real-World Validation of Molecular International Prognostic Scoring System for Myelodysplastic Syndromes. Journal of Clinical Oncology, 2023
  4. P Fenaux. Myelodysplastic syndromes: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up†☆.. Annals of oncology : official journal of the European Society for Medical Oncology, 2020
  5. M. Pfeilstöcker. Time-dependent changes in mortality and transformation risk in MDS.. Blood, 2016
  6. F. Baidoun. Clinical Outcome of Patients Diagnosed with Myelodysplastic Syndrome-Unclassifiable (MDS-U): Single Center Experience. Blood, 2014
  7. M. Voso. Revised International Prognostic Scoring System (IPSS) predicts survival and leukemic evolution of myelodysplastic syndromes significantly better than IPSS and WHO Prognostic Scoring System: validation by the Gruppo Romano Mielodisplasie Italian Regional Database.. Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2013
  8. L. Swart. Validation Of The Revised International Prognostic Scoring System (IPSS-R) In 1000 Newly Diagnosed MDS Patients With Low- and Intermediate-1 Risk MDS In The European Leukemianet MDS (EUMDS) Registry. Blood, 2013
  9. S. N. Park. Application Of The Revised International Prognostic Scoring System In Korean Patients With MDS and Clinical Significance Of Clonal Evolution. Blood, 2013
  10. M. Litzow. A Novel Prognostic Model To Predict Relapse After Allogeneic Stem Cell Transplantation For Myelodysplastic Syndromes. Blood, 2013
  11. T. Field. Utility Of Revised International Prognostic Scoring System (R-IPSS) To Predict Outcome Of Myelodysplastic Syndromes (MDS) Patients After Allogeneic Hematopoietic Stem Cell Transplantation (AHSCT). Blood, 2013
  12. A. Mishra. Validation of the Revised International Prognostic Scoring System (R-IPSS) for Patients with Myelodysplastic Syndromes: Therapeutic Implications.. Blood, 2012